These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16011526)

  • 21. Protease inhibitors: the current status.
    Dauer B
    J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiretroviral pipeline: new-drug reports from retroviruses conference.
    James JS
    AIDS Treat News; 2004 Feb; (398):1-2. PubMed ID: 15119288
    [No Abstract]   [Full Text] [Related]  

  • 23. Some existing drugs work on resistant HIV.
    AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
    AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
    [No Abstract]   [Full Text] [Related]  

  • 25. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 26. [Reverse transcriptase inhibitors, protease inhibitors].
    Tachikawa N
    Nihon Rinsho; 2012 Apr; 70(4):579-95. PubMed ID: 22568138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretrovirals.
    Temesgen Z; Wright AJ
    Mayo Clin Proc; 1999 Dec; 74(12):1284-301. PubMed ID: 10593358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
    Audelin AM; Lebech AM; Petersen AB; Jørgensen LB
    J Med Virol; 2008 Aug; 80(8):1319-21. PubMed ID: 18551616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
    Moutschen M; Nkoghe D; Léonard P; Demonty J
    Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
    [No Abstract]   [Full Text] [Related]  

  • 33. New drugs in development.
    Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising new agents on the horizon.
    Feinberg J
    AIDS Clin Care; 2002 Mar; 14(3):22. PubMed ID: 12141239
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
    Pierone G; Urban T; Martin A; Mieras J; Kantor C
    HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
    [No Abstract]   [Full Text] [Related]  

  • 37. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
    Hall D
    HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
    [No Abstract]   [Full Text] [Related]  

  • 38. [Zalcitabine].
    Enferm Infecc Microbiol Clin; 1997 Mar; 15(3):177-8. PubMed ID: 9235070
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
    Hammond JL; Parikh UM; Koontz DL; Schlueter-Wirtz S; Chu CK; Bazmi HZ; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3930-2. PubMed ID: 16127074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.